Clinical Trial

A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

Study acronym: ENERGIZEKids-T
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to compare the effect of mitapivat versus placebo on transfusion burden in pediatric participants with α- or β-transfusion-dependent thalassemia.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-04
Trial Details
NCT Number NCT07506863
Lead Sponsor Agios Pharmaceuticals, Inc.
Conditions Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
Enrollment 54 participants
Start Date 2026-09
Primary Completion 2029-06 (estimated)
Study Completion 2032-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-03